Iterum Therapeutics (NASDAQ:ITRM) Trading Up 2.2%

Iterum Therapeutics plc (NASDAQ:ITRM)’s share price shot up 2.2% during mid-day trading on Friday . The stock traded as high as $1.72 and last traded at $1.64. 442,337 shares were traded during mid-day trading, an increase of 21% from the average session volume of 365,530 shares. The stock had previously closed at $1.61.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of Iterum Therapeutics in a report on Friday, June 21st.

Iterum Therapeutics Price Performance

The firm’s fifty day moving average price is $1.34 and its 200-day moving average price is $1.53. The firm has a market capitalization of $27.16 million, a P/E ratio of -0.62 and a beta of 2.26.

Iterum Therapeutics (NASDAQ:ITRM) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.11. Analysts expect that Iterum Therapeutics plc will post -1.76 earnings per share for the current year.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.